Analyst Ratings For bluebird bio Inc (NASDAQ:BLUE)
Today, Maxim Group reiterated its Hold rating on bluebird bio Inc (NASDAQ:BLUE).
There are 17 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on bluebird bio Inc (NASDAQ:BLUE) is Buy with a consensus target price of $204.2105 per share, a potential 66.17% upside.
Some recent analyst ratings include
- 12/3/2018-bluebird bio Inc (NASDAQ:BLUE) had its Hold rating reiterated by Maxim Group
- 11/27/2018-bluebird bio Inc (NASDAQ:BLUE) had its Hold rating reiterated by Oppenheimer
- 11/27/2018-bluebird bio Inc (NASDAQ:BLUE) has coverage initiated with a Outperform rating and $145.00 price target
- 11/14/2018-bluebird bio Inc (NASDAQ:BLUE) gets upgraded to Outperform by Sanford C. Bernstein with a price target of $155.00
Recent Trading Activity for bluebird bio Inc (NASDAQ:BLUE)
Shares of bluebird bio Inc closed the previous trading session at 122.89 −2.25 1.80% with shares trading hands.